Knee Osteoarthritis Drugs Market Size & Growth Forecast 2027–2036, By Segments (Route of Administration, Drug Type, Age Group), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Route of Administration Segment Analysis: Parenteral (Largest & Fastest-Growing Segment)

In 2026, the parenteral route of administration accounts for a 52.84% share of the knee osteoarthritis drugs market, reflecting the established role of injectable treatments in managing joint pain and inflammation among patients who require targeted symptom relief. Parenteral therapies, including intra-articular injections, can deliver medication directly into or around the affected joint, depending on the treatment, making them an important option for patients whose symptoms remain inadequately controlled through other approaches. These treatments may include corticosteroids and hyaluronic acid preparations, while other injectable therapies may be used according to clinical guidelines and individual patient needs. The segment's position is supported by demand for alternatives to oral medications, particularly among patients who experience gastrointestinal intolerance, have contraindications to certain drugs, or seek localized treatment. Clinical decisions depend on symptom severity, joint condition, patient history, expected duration of relief, and the evidence supporting each therapy. The growing emphasis on individualized osteoarthritis management and the need to address persistent knee pain continue to support interest in injectable treatments. However, effectiveness and duration of benefit vary by product and patient, and repeated injections may involve limitations or risks that require clinical consideration. Advances in injection formulations, administration techniques, and patient selection may influence future adoption, while ongoing evaluation of safety, cost, and clinical outcomes will remain central to the knee osteoarthritis drugs market development in 2026.

Drug Type Segment Analysis: Non-steroidal Anti-Inflammatory Drugs (NSAIDs) (Largest & Fastest-Growing Segment)

Non-steroidal anti-inflammatory drugs (NSAIDs) account for a 38.66% market share of the knee osteoarthritis drugs industry in 2026, reflecting their established role in managing pain and inflammation associated with the condition. NSAIDs are widely used because they can provide symptomatic relief and are available in oral and topical formulations, allowing treatment choices to be adapted to patient needs and tolerability. Oral NSAIDs may be considered when broader pain relief is required, whereas topical formulations can offer localized treatment with lower systemic exposure, although risks are not eliminated. Their established clinical use, familiarity among healthcare professionals, and availability across different treatment settings support continued demand. The segment's growth is also influenced by the prevalence of knee osteoarthritis, the need to maintain mobility and daily functioning, and the continuing use of pharmacological therapy alongside exercise, weight management, and other non-drug interventions. Treatment selection requires careful consideration of age, cardiovascular risk, kidney function, gastrointestinal history, concurrent medications, and overall health, as NSAIDs can cause significant adverse effects in some patients. Manufacturers and healthcare providers therefore have an important role in supporting appropriate product selection, clear safety information, and adherence to recommended dosing. Continued demand for accessible symptom management, alongside formulation improvements and greater attention to patient-specific risk profiles, supports the importance of NSAIDs in the knee osteoarthritis drugs market in 2026.

Age Group Segment Analysis: Above 65 (Largest & Fastest-Growing Segment)

The above-65 age group represents the leading and fastest-growing age segment in 2026, holding a dominant market share in the knee osteoarthritis drugs market due to the strong association between advancing age and the prevalence of degenerative joint conditions. As cartilage deterioration and other structural changes accumulate over time, older adults are more likely to experience knee pain, stiffness, reduced mobility, and difficulties performing everyday activities. These symptoms can increase the need for sustained management strategies that use medication in conjunction with physical activity, rehabilitation, weight management where appropriate, and other interventions designed to preserve joint function. Drug treatment in this age group requires particular attention because older patients are more likely to have multiple chronic conditions and use several medications simultaneously. Oral analgesics and NSAIDs may provide symptom relief, while topical treatments and selected injectable therapies can offer additional options depending on clinical circumstances. However, treatment decisions must account for potential gastrointestinal, cardiovascular, renal, and drug-interaction risks, making individualized assessment especially important. Growing demand for care that preserves independence and quality of life supports the segment's continued prominence. Opportunities for market development are linked to safer treatment strategies, improved tolerability, better patient education, and approaches that integrate pharmacological management with broader osteoarthritis care. As healthcare systems respond to the needs of aging populations, effective and appropriately tailored knee osteoarthritis treatment is likely to remain an important priority in 2026.